NASH UPDATE ON DIAGNOSTICS AND THERAPY. Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine
|
|
- Elijah Price
- 6 years ago
- Views:
Transcription
1 NASH UPDATE ON DIAGNOSTICS AND THERAPY Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine Conflicts of interest Salaried employee: of VCU Member of Board: McGuire VA Research Institute, unpaid member Ad hoc consultant: Salix: < $ 5K Ikaria: < $ 5K Abbott: $5-10K Bristol-Myers: < $ 5K Genfit: $ 5-10 K Genentech: < $ 5K Bristol Myers: < $ 5K Echosens: unpaid consultant Gilead: unpaid consultant Novartis: unpaid consultant Takeda: unpaid consultant Royalties: Elsevier- Boyers Textbook of Hepatology: < $ 5K Uptodate:<$5K Uptodate: < $ 5K Grants (awarded to university): NIH: $ 1.5 million annual direct costs Roche, Gilead, Astellas: $ 25-50K total Salix, Ikaria: $ each Gilead: $ 150 K annual direct costs based on recruitment Genfit: US PI for GFT505 trial Galectin: $ 30000
2 NASH and associated morbidity Risk factors for progression Age Obesity DM CVD Risk HCC Risk Hepatic Decompensation Progression Abbreviations: CVD, cardiovascular disease; DM, diabetes mellitus; HCC, hepatocellular carcinoma. Managing NAFLD in 3 simple steps IS NAFLD PRESENT? IS INTERVENTION NEEDED? WHAT INTERVENTION?
3 When to suspect NAFLD is present? Presence of risk factors: overweight-obesity it features of metabolic syndrome- especially T2DM Presence of liver injury without other causes: abnormal AST, ALT (invariably below 250 IU/l) negative HCV, HBV, hemochromatosis, Wilson disease, alpha1 antitrypsin i and high-titer h i ANA Direct evidence of increased hepatic fat: imaging (US, CT scan, MRI) MR-based proton density fat fraction estimation of steatosis CAP for fibroscan: - Point of care - AUC 0.85 with steatosis t grade (AASLD 2015) - CAP > 250 = steatosis Liver Fat index: based on clinical parameters An Tang et al, radiology, Epub 2014)
4 Managing NAFLD in 3 simple steps IS NAFLD PRESENT? IS INTERVENTION NEEDED? WHAT INTERVENTION? Presence of steatohepatitis and severity of fibrosis relate to outcomes Angulo et al, Gastroenterology, Gastroenterology Aug;149(2):
5 Time to First Liver-Related Event Low APRI and FIB-4 Event Free A FIB4 > 3 in someone over Age 40 yrs is associated with 20% risk of a liver event within 5 yrs APRI >1.50 or FIB-4 > Time (days) # at risk: Low # at risk: High Nguyen et al, Publication under review 2015 Fibroscan for NASH fibrosis Inter-observer concordance 0.96 For NASH (n > 500) Yoneda et al, Digestive and Liver Disease, 2007; Epub
6 Magnetic resonance elastography is superior to clinical prediction models for determination of advanced fibrosis in patients with non-alcoholic fatty liver disease: A prospective study Primary outcome: 2D-MRE vs. FIB-4 ROC curve of 2D-MRE AUROC 1.0 p= AUROC: p< D-MRE FIB-4 p-value: AUROC of 2D-MRE vs. FIB-4 DeLong Test Misclassifications: ifi 2D-MRE: 10 patients FIB-4: 5 patients (combination of upper and lower cutoffs) 33 patients in FIB-4 indeterminate range 25/33 correctly identified by 2D-MRE Cui JY, et al. EASL 2015, Vienna. #O020 One could use FIB-4 upper cut-point to rule in, and lower cut-point to rule out, and those in the intermediate range may be candidates for MRE assessment, to avoid a liver biopsy for detection of advanced fibrosis These strategies could be considered for inclusion into clinical trials for assessing efficacy of anti-fibrotic therapies in NASH Work up of NAFLD: who to biopsy? Suspected NAFLD Features of Met S FIB4, NAFLD fibrosis score Age Age < 40 FIB4 < 2 No Features of MetS except obesity Multiple features of MetS Fibroscan > 6 kp MRE > 2.9 kp Age > 50 FIB4 > 3, APRI > 1.5 Multiple features of MetS Fibroscan or MRE Life style intervention Monitor Consider rpt fibroscan x yearly Liver Bx indeterminate Confirm advanced disease > 12 Kp on FS
7 MELD less than 10 is associated with low short-term mortality MELD > 10 MELD < 10 Ripoll et al, GASTROENTEROLOGY 2007;133:4 Risk stratification of NASH Evaluate alcohol consumption Suspected NAFLD (steatosis on imaging +/- elevated ALT) Confirmed NAFLD Exclude alternate causes of ALT e.g. HCV Non-invasive risk stratification (use biopsy when non-invasive tests are indeterminate) Low risk profile - Steatosis alone on LBx - Normal lalt - Age < 40 yrs - Absence of T2DM, HTN - Low FIB4/APRI - Fibroscan < 5 kps Intermediate risk - Steatohepatitis^ - BMI > Stage Multiple features MetS - Increasing age - Elevated ALT - Fibroscan > 6 < 12 kps High risk profile - Steatohepatitis stage 4^ - Type 2 DM - FIB4 > 3, APRI > Fibroscan > 12 kps - MELD > 10* - HVPG > 10 mm Hg* Rinella and Sanyal, Nature Reviews Gastroenterology, 2015 in press
8 Managing NAFLD in 3 simple steps IS NAFLD PRESENT? IS INTERVENTION NEEDED? WHAT INTERVENTION? A variety of dietary approaches can produce weight loss in overweight and obese adults if reduction in dietary energy intake is achieved 1,200-1,500 kcal/d for women, or energy deficit 500 kcal/d gy 1,500-1,800 kcal/d for men, or energy deficit 750 kcal/d 30% energy deficit Strength of Evidence: High
9 ) Weight loss (%) Weight loss intensity is strongly associated to improvement of histological parameters in patients with nonalcoholic steatohepatitis after 52 weeks of lifestyle modification Correlations* between WL and steatohepatitis resolution 20 Rho=0.55, p< No Yes Resolution of steatohepatitis Weight loss (% %) Correlations between WL and fibrosis status at the end of intervention 20 Rho=0.13, p= Fibrosis Worsened Stabilized Fibrosis status Regressed No significant correlation was found with changes in the physical activity score at the end of the intervention Everyone who resolved steatohepatitis had weight loss Everybody with weight loss did not resolve hepatitis The data for fibrosis are inconclusive Vilar-Gomez E, et al. EASL 2015, Vienna. #O042 Is a little bit of alcohol safe or even beneficial in subjects with NAFLD?? Decreased liver disease? Increased HCC
10 What are the potential targets for therapeutics for NASH Insulin sensitizers Insulin resistance FFA + insulin+ cytokines Steatosis + metabolic dysregulation ER stress Oxidative stress Mitochondrial injury Anti oxidants Inflammatory Apoptosis signaling Cell death Stellate cell activation Multiple sources fibrosis Efficacy of anti-nash therapies (only drugs that have undergone phase 2B trials shown) Table 1. Effects of four anti-nash treatments on decrease in NAFLD activity scores Histologic Improvement Group % x/n OR 95% CI P Vitamin E 45% 70/ , 4.7 < No Vitamin E (Placebo) 22% 42/ Pioglitazone 56% 39/ , Placebo 24% 17/ Metformin 48% 24/ , Placebo 26% 12/ Obeticholic acid 49% 50/ , Placebo 23% 23/ Kowdley et al for NASH CRN, EASL 2015
11 Vitamin E and Pioglitazone resolve NASH Table 2. Effects of four anti-nash treatments on resolution of NASH Resolution of NASH Group % x/n OR 95% CI P Vitamin E 38% 56/ , 3.9 <0.001 No Vitamin E (Placebo) 20% 37/ Pioglitazone 47% 33/ , Placebo 21% 15/ Metformin 41% 16/ , Placebo 28% 11/ Obeticholic acid 22% 22/ , Placebo 13% 13/ Kowdley et al for NASH CRN, EASL 2015 What s beyond vitamin E and glitazones?
12 Therapeutic landscape for NASH (phase 2-3 trials) October 22, 2014, Clinicaltrials.gov Obeticholic Acid -6α-Ethyl Chenodeoxycholic Acid - INT-747 CDCA chenodeoxycholic acid Semi-Synthetic Synthetic Derivative of Chenodeoxycholic Acid INT-747 6α-ethyl chenodeoxycholic acid FXR EC 50 (agonism) 8.66 μm ~ 100x FXR agonism μm Pelliciari R. J.Med.Chem 2002
13 FLINT: Primary and Secondary Histological Endpoints 70% 60% 50% % of Patients w/ Improvement OCA Pbo P= P=0.001 P=0.006 P=0.03 P=0.004 P=0.08 P= % 53% 45% 46% 40% 30% 20% 10% 21% 38% 35% 31% 35% 19% 22% 13% 12% 13% 0% Primary Endpoint Steatosis Lobular Inflammation Ballooning Fibrosis NASH resolution Portal Inflammation 1: Data from Tetri et al. The Lancet. Published online November 7, : All p-values compared to placebo. P-value calculated with the Cochran-Mantel-Haenszel test, stratified by clinic and diabetes status. 45% 40% 35% FLINT: Fibrosis Improvement Across Baseline Fibrosis Scores P=0.004 % of Patients w/ 1-stage Improvement not sig. 35% 35% P= % OCA Pbo 30% 25% 20% 15% 19% 14% 25% 10% 5% 0% N=102 N=98 N=31 N=21 N=60 N=61 Total Group F1 F2 & F3 1: Data from Tetri et al. The Lancet and Supplementary Appendix. Published online November 7, : All p-values compared to placebo. P-values for Intercept analyses estimated by Intercept using Fisher s Exact test on published data in Supplementary Appendix, but not stratified.
14 Obeticholic acid for NASH: Benefits in a high risk subgroup and the effects of concomitant statin use No statin Baseline statin New statin OCA-no statin Placebo-no statin ti OCA-baseline statin Placebo-baseline b li Statinti OCA-new statin Placebo-new Statinti Mean LDL-C (mg/dl) LS mean (SE) 16.0 (3.5) *** LS mean (SE) 8.7 (4.6) LS mean (SE) (5.9) ** Visit week EOT Visit week EOT Visit week EOT No statin ***p<0.0001, baseline statin p=0.0597, new statin **p= Sensitivity analysis of FLINT trial subsets of patients demonstrates efficacy of OCA for histologic improvement of NASH OCA induces an increase in LDL cholesterol; in statin naive patients, this can be reduced by statins Sanyal A, et al. EASL 2015, Vienna. #LP18 Liraglutide improved NASH in a multicenter, doubleblinded, randomised, placebo-controlled phase II trial Patients, % Primary endpoint: NASH resolution with no worsening of fibrosis 60 p< Liraglutide (n=23) Placebo (n=22) Secondary endpoints Liraglutide (n=23) Placebo (n=22) Kleiner fibrosis -0.2 (0.8) 0.2 (1.0) Improvement, n (%) 6 (26.1) 3 (13.6) Worsening, n (%) 2 (8.7)* 8 (36.4) *p<0.05 vs placebo More diarrhea with liraglutide Liraglutide, a long-acting GLP-1 agonist dosed once daily SC, with overall benefits in T2DM Results replicated here; patients showed significant histological resolution of NASH Long-term and larger studies with liraglutide or other GLP-1 agonists in NASH are warranted Armstrong MJ, et al. EASL 2015, Vienna. #G01
15 Improvement of NASH by PPARα/δ activation Metabolic Syndrome Macrophages Visceral and liver fat & inflammation Hepatocytes PPARδ PPARα Inflammatory Cytokines Metabolic Control FA and lipoprotein metabolism Tailleux, Wouters & Staels BBA 2012 ;1821: Results: Evolution of Fibrosis after surgery Fibrosis improves after bariatric surgery 100% 3.75% 7.5% 7.5% 90% 13.75% 80% 21.25% 70% 60% 32.5% 2.5% Metavir scale % 40% 40% 2 30% 20% 10% 27.5% 43.75% 1 0 0% Before After p<0.003 Histologic feature Improvement p Value Fibrosis (Kleiner score) 33.8% p<0.003 Mathurin et al, AASLD 2014
16 Outcomes in subjects with cirrhosis undergoing a variety of bariatric procedures Parameter Nor% Total # of subjects 122 (60% female) # Child Pugh A 96.5% Complications 21.3% Decompensation 6.55% Early mortality 1.6% Late mortality 25% 2.5% Jan et al, Obes Surg 2015, epub May 16 Management of NAFLD by disease stage Low risk Intermediate risk High risk Lifestyle intervention Pharmaco ological therapy Bariatric Surge ery HCC and EV screening
17 Thank You Courtesy- Dr. David Kleiner
Defining the gold standard in biomarker validation for NASH
Defining the gold standard in biomarker validation for NASH Arun J Sanyal M.D. Professor of Medicine, Physiology and Molecular Pathology Virginia Commonwealth University School of Medicine Conflicts of
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationNon-alcoholic fatty liver disease: time to take note and manage. Philip Newsome Professor of Hepatology & Director of Centre for Liver Research
Non-alcoholic fatty liver disease: time to take note and manage Philip Newsome Professor of Hepatology & Director of Centre for Liver Research Disclosures Consultancy, Co-ordinating Investigator roles
More informationFatty Liver Disease A growing epidemic
Fatty Liver Disease A growing epidemic Updates in GIM for Primary Care Don C. Rockey March 9 th, 2018 Disclosures 2018 Research Funding (all to MUSC) NIH/NIDDK Actelion Pharmaceuticals Gilead Sciences
More informationUpdate on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
More informationNAFLD: US GUIDELINES. US Guidelines for NAFLD
NAFLD: US GUIDELINES Arun J Sanyal M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University School of Medicine US Guidelines for NAFLD Represents consensus amongst AGA, AASLD and ACG
More informationMETABOLIC SYNDROME AND HCV: FROM HCV
METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,
More informationNonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationNONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
More informationNAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
More informationWHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH?
WHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH? Helena Cortez-Pinto Laboratório de Nutrição, FML, Serviço de Gastrenterologia, Hospital St Maria, Lisboa, Portugal EASL Governing Board:
More informationNormal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos
Fatty liver disease Its not just for big boys anymore Ken Flora, MD, FAASLD, FACG, AGAF No disclosures Common situation Normal ALT for men 30 IU/L 36% US males abnormal Normal ALT for women 20 IU/L 28%
More informationNAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
NAFLD & NASH Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology Indiana University School of Medicine ACG Midwest Regional Course,
More informationThe Skinny On Non Alcoholic Fatty Liver Disease
The Skinny On Non Alcoholic Fatty Liver Disease UCSF Advances in Internal Medicine Monika Sarkar, MD, MAS UCSF Division of GI/Hepatology June 24th, 2015 Non Alcoholic Fatty Liver Disease: Outline Pathogenesis
More informationAt Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
More informationInvestigating general liver disease/transaminitis
BHIVA Autumn Conference London 14 October 2016 Investigating general liver disease/transaminitis Emmanuel A. Tsochatzis Senior Clinical Lecturer and Consultant Hepatologist Institute for Liver and Digestive
More informationStudy Design to Validate Biomarkers of Therapeutic Response in Pre-cirrhotic NASH
Study Design to Validate Biomarkers of Therapeutic Response in Pre-cirrhotic NASH Brent A. Neuschwander-Tetri, MD, FAASLD Professor of Internal Medicine Director, Division of Gastroenterology and Hepatology
More informationNONALCOHOLIC FATTY LIVER DISEASE
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD, MSc Hepatology and Liver Transplantation University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Terminology Pathogenesis
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease Varun Saxena, MD MAS Gastroenterology and Hepatology Kaiser Permanente South San Francisco Assistant Clinical Professor University of California San Francisco January
More informationAdvances in Understanding Hepatic Fibrosis and Chronic Liver Disease
Advances in Understanding Hepatic Fibrosis and Chronic Liver Disease Scott Friedman, M.D. Fishberg Professor of Medicine Dean for Therapeutic Discovery Chief, Division of Liver Diseases Icahn School of
More informationNAFLD 2017 Identifying and managing disease while waiting for a cure
NAFLD 2017 Identifying and managing disease while waiting for a cure A. Sidney Barritt IV, MD, MSCR Associate Professor of Medicine UNC Liver Center High Impact Hepatology 4 November 2017 Disclosures I
More informationNon-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know
Non-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
More informationFatty Liver Disease. Mark Thursz. Imperial College
Fatty Liver Disease Mark Thursz Imperial College Non-Alcoholic Fatty Liver Disease UK adult obesity (BMI>30) 1980: 6% [M], 8% [F]. 1997: 17% [M], 20% [F]. By 2004, 23.6% of men and 23.8% of women were
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationNovel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Alina M. Allen, Meng Yin, Sudhakar K. Venkatesh, Taofic Mounajjed, Todd A. Kellogg,
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationFirst European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health
First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,
More informationAn Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications
REVIEW An Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications Naim Alkhouri, M.D.,*, and Andrea Scott, B.S.* Nonalcoholic fatty liver disease (NAFLD)
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationPREVALENCE OF NAFLD & NASH
- - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)
More informationNAFLD: ACG Southern Regional Course Nashville, TN. Speaking - None
NAFLD: 2015 Naga Chalasani, MD, FACG David W. Crabb Professor of Medicine Director, Division of GI and Hepatology Indiana University School of Medicine ACG Southern Regional Course Nashville, TN Disclosures
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationLiver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York
Liver Pathology and the Clinician in 2015: At the Crossroads Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York DISCLOSURES Consultant for: Salix Merck Gilead BMS Synageva Research funding:
More information2 nd International Workshop on NASH Biomarkers, Washington DC, May 5-6, 2017
Hepatic Proton Density Fat Fraction Correlates With Histologic Measures of Steatosis and Is Responsive to Changes in Those Measures in a Multi-center Nonalcoholic Steatohepatitis Clinical Trial Michael
More informationInternal Medicine Grand Rounds University of Texas Southwestern Medical Center October 5, 2018
Internal Medicine Grand Rounds University of Texas Southwestern Medical Center October 5, 2018 Nonalcoholic Fatty Liver Disease (NAFLD) Turns 38-What Have We Learned? Jay D. Horton, M.D. This is to acknowledge
More informationUpdate on Clinical Management
Non-Alcoholic Fatty Liver Disease Update on Clinical Management Lisa J. Yoo, D.O. Gastroenterologist Regional Gastroenterology INTRODUCTION Non-alcoholic fatty liver disease (NAFLD) is characterized by
More informationNonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup
REVIEW REVIEW Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup Puneet Puri, M.B.B.S., M.D. and Arun J. Sanyal, M.B.B.S., M.D. Nonalcoholic fatty liver disease (NAFLD) is defined
More informationPEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE
PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based
More informationLipid and Bile Acids as NAFLD- Related Biomarkers
Lipid and Bile Acids as NAFLD- Related Biomarkers Puneet Puri, MBBS, MD Division of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University, Richmond, VA 1st International Workshop
More informationClinical Trials & Endpoints in NASH Cirrhosis
Clinical Trials & Endpoints in NASH Cirrhosis April 25, 2018 Peter G. Traber, MD CEO & CMO, Galectin Therapeutics 2018 Galectin Therapeutics NASDAQ: GALT For more information, see galectintherapeutics.com
More informationFatty liver disease: What do we know?
Fatty liver disease: What do we know? Prof. Dr. Claus Niederau Katholische Kliniken Oberhausen ggmbh St. Josef-Hospital Academic Teaching Hospital University of Duisburg-Essen NAFLD Non-Alcoholic Fatty
More informationNAFLD & NASH: Russian perspective
NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received
More informationConflicts of Interest in the last 12 months
STEATOHEPATITIS Richard K. Sterling, MD, MSc, FACP, FACG VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Richmond, VA Conflicts of Interest in the last
More informationNAFLD and NASH The next Tsunami in liver disease Are we ready?
NAFLD and NASH The next Tsunami in liver disease Are we ready? Mary Pat Pauly MD FACP AASLD Gastroenterology and Liver Disease Kaiser Permanente, Sacramento Clinical Professor of Internal Medicine and
More informationNAFLD DIAGNOSIS AND MANAGEMENT: MOVING FROM THE DARK AGES TO THE RENAISSANCE
NAFLD DIAGNOSIS AND MANAGEMENT: MOVING FROM THE DARK AGES TO THE RENAISSANCE Dr. Thomas Jensen M.D., Assistant Professor Medicine Dr. Amanda Wieland M.D., Assistant Professor of Medicine OBJECTIVES Recognize
More informationWhat is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob
Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:
More informationFatty Liver in HIV. Richard K. Sterling, MD, MSc, FACP, FACG
Fatty Liver in HIV Richard K. Sterling, MD, MSc, FACP, FACG Professor of Medicine Chief, Section of Hepatology Director, HIV-Liver Disease Virginia Commonwealth University Liver-Related Deaths in HIV 1246
More informationOverview of the Clinical Trial Data on Non-alcoholic Steatohepatitis (NASH)
Overview of the Clinical Trial Data on Non-alcoholic Steatohepatitis (NASH) Brent A. Neuschwander-Tetri, MD, FACP, FACG, AGAF, FAASLD Professor of Internal Medicine Director, Division of Gastroenterology
More informationCDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health
CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health Obesity and NAFLD Definitions: Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver
More informationNASH PROGRESS IN THE LAST DECADE
PROGRESS IN THE LAST DECADE Mitchell L. Shiffman, MD, FACG Director Health System Richmond and Newport News, VA Medical Group Good Help to Those in Need A GLOBAL HEALTH PROBLEM Nigeria Australia Spain
More informationNAFLD and NASH: The Not-So-New Kids on the Block
NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an
More informationA pathologist, a radiologist and a hepatologist walked into a bar
A pathologist, a radiologist and a hepatologist walked into a bar Brent A. Neuschwander-Tetri, MD, FAASLD Professor of Internal Medicine Director, Division of Gastroenterology and Hepatology Saint Louis
More informationTherapeutic Approaches to Cirrhotic versus Pre-Cirrhotic NASH
www.alacrita.com Therapeutic Approaches to Cirrhotic versus Pre-Cirrhotic NASH 2nd Annual NASH Summit Europe October 23-24, 2018 Frankfort, Germany Peter G. Traber, MD Partner, Alacrita Consulting Alacrita
More informationDisclosures. The Typical Therapeutic Pyramid $$$ The NAFLD Umbrella. The Big Question: What are the treatment options for NASH?
Disclosures I have the following relationships to disclose: Ethicon Endo Surgery Inc. Galectin Therapeutics Synageva Biopharma Raptor Pharmaceuticals I will be discussing off label use of medications in
More information6/28/2017. Update in NAFLD. Key Points. NAFLD: Epidemiology. US Population: million. NALFD Prevalence 25% 80 million
Update in NAFLD PHILLIP K HENDERSON, DO ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE INSTRUCTOR OF SURGERY, DIVISION OF TRANSPLANT SURGERY UNIVERSITY OF ALABAMA AT BIRMINGHAM
More informationGOLDEN-505 STUDY EASL INVESTOR EVENT. Vienna April 24, 2015
GOLDEN-505 STUDY EASL INVESTOR EVENT Vienna April 24, 2015 1 Disclaimer Important Information and Forward Looking Statements GENFIT IS A PUBLIC COMPANY LISTED ON EURONEXT PARIS (COMPARTMENT B) STOCK EXCHANGE
More informationHow to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris
How to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris CLINICAL CASE 1996. 54 years old female Department of Primary CV Prevention
More informationTherapy for NAFLD Are we getting there? Sanjay Bhagani Royal Free London/UCL
Therapy for NAFLD Are we getting there? Sanjay Bhagani Royal Free London/UCL What is NAFLD? Non-Alcoholic Fatty Liver Disease Wide disease range from simple steatosis to cirrhosis Steatosis Steatosis/inflammation
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abetalipoproteinemia NASH and, 537 Acquired errors of metabolism NASH and, 536 537 Amiodarone steatohepatitis due to, 527 Anticonvulsant mood
More informationLaboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
More informationLiver Pathology in the 0bese
Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
More informationNONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH
NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH Bachir Taouli, MD Director of Body MRI and Cancer Imaging Program Department of Radiology / Translational and Molecular Imaging Institute
More informationTherapeutic targets and the management of NASH
Therapeutic targets and the management of NASH Joo Hyun Sohn, MD. Professor of Medicine, College of Medicine, Hanyang University Division of Gastroenterology and Hepatology Hanyang University Guri Hospital
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationNAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
More informationEarly life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem
More informationFATTY LIVER DISEASE (NAFLD) (NASH) A GROWING
NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams
More informationAASLD Immune tolerant phase HBV NAFLD diagnostic HCC
AASLD 2016 Immune tolerant phase HBV NAFLD diagnostic HCC Immune tolerant 3 Modified from Chan HLY and Wong VWS. Hepatitis B. In Zakim and Boyers s Hepatology 2012 2015 AMERICAN ASSOCIATION FOR THE S1T6UDY
More informationEvercore ISI Presentation- Madrigal
Evercore ISI Presentation- Madrigal Forward-Looking Statements Any statements, other than statements of historical facts, made in this presentation regarding our clinical studies and our research and development
More informationTreatment of NASH: What Helps Beyond Weight Loss?
THE RED SECTION 821 see related editorial on page x Treatment of NASH: What Helps Beyond Weight Loss? Bubu A. Banini, MD, PhD1 and Arun J. Sanyal, MBBS, MD1 Am J Gastroenterol 2017; 112:821 824; doi: 10.1038/ajg.2017.83;
More informationFDA Introductory Remarks Stephanie O. Omokaro, MD
FDA Introductory Remarks Stephanie O. Omokaro, MD Division of Gastroenterology & Inborn Errors Products (DGIEP) Center for Drug Evaluation and Research Office of New Drugs Office of Drug Evaluation III
More informationPreface: Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic
NASH and NAFLD Preface: Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic David E. Bernstein xiii Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationWORKSHOP. How to manage patients with NASH? Pr Jérôme Boursier Angers, France
WORKSHOP How to manage patients with NASH? Pr Jérôme Boursier Angers, France 11th Paris Hepatology Conference January 16th, 2018 Clinical case Man Man63 63years yearsold, old,referred referredby byhis
More informationCompany Overview. September 2018 NASDAQ: MDGL
Company Overview September 2018 NASDAQ: MDGL 1 Forward Looking Statements Any statements, other than statements of historical facts, made in this presentation regarding our future financial or business
More informationALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche,
Supplemental Methods Analytical determinations ALT and aspartate aminotransferase (AST) levels were measured using the α-ketoglutarate reaction (Roche, Basel, Switzerland). Glucose, triglyceride, total
More informationDietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and
Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic
More informationtage Percent Total & over Total & over Men Women Men Women
Paul Angulo, MD, FACG, AGAF Professor of Medicine, Section Chief of Hepatology Division i i of Digestive i Diseases and Nutrition i University of Kentucky Medical Center Lexington, KY Paul Angulo, MD University
More informationThe EMA reflection paper on chronic liver disease and its implications for drug development in NASH
The on chronic liver disease and its implications for drug development in NASH Content of the reflection paper and report from stakeholder meeting Elmer Schabel MD No conflict of interest. Content Overview:
More informationYun-Jung Choi, Jiangao Song, Jeff D. Johnson, Charles McWherter. NASH-TAG Conference Park City, Utah January 4, 2019
Combination Therapy of Seladelpar and Liraglutide Attenuates Obesity, Hepatic Steatosis and Fibrosis in a Diet-induced and Biopsy-confirmed Mouse Model of NASH Yun-Jung Choi, Jiangao Song, Jeff D. Johnson,
More informationEASL International Liver Congress Paris, France 14 April 2018
NGM282 Improves Fibrosis and NASH-Related Histology in 12 Weeks in Patients With Biopsy-Confirmed NASH, Which is Preceded By Significant Decreases in Hepatic Steatosis, Liver Transaminases and Fibrosis
More informationTransient elastography in chronic liver diseases of other etiologies
4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia
More informationIn Search of New Biomarkers for Nonalcoholic Fatty Liver Disease
REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general
More informationWHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF
WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF ctliver@fegato.it Worldwide estimated prevalence of NAFLD distribution of PNPLA3 genotypes 2017-Younussi
More informationPrognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014
Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic
More informationPretreatment Evaluation
Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University
More informationLiver biopsy as the gold standard for diagnosis. Pierre BEDOSSA
Liver biopsy as the gold standard for diagnosis Pierre BEDOSSA 1 PATHOLOGY OF NAFLD CONFLICTS OF INTEREST Grants and funding from Genfit, Intercept, Allergan, Inventiva, OWL, Echosens CEO and funding of
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationWhen to Treat: Staging Liver Disease David L. Thomas, MD, MPH
When to Treat: Staging Liver Disease David L. Thomas, MD, MPH Professor of Medicine Johns Hopkins School of Medicine Disclosures Received royalties from UpToDate, Inc. Staging refers to the assessment
More informationEASL EASD EASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease.
Commentary. EASL EASD EASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease. Christopher D. Byrne 1,2, Giovanni Targher 3 1 Nutrition and Metabolism, Faculty of Medicine,
More informationJan vp24.i. GENFIT Overview. January 2014
Jan 2014. vp24.i GENFIT Overview January 2014 1 Disclaimer Forward Looking Statement GENFIT IS A PUBLIC COMPANY LISTED ON NYSE EURONEXT (ALTERNEXT PARIS) STOCK EXCHANGE SINCE 2006. THIS DOCUMENT DOES NOT
More informationINVESTOR PRESENTATION. November 16 th, 2015
INVESTOR PRESENTATION November 16 th, 2015 1 Disclaimer Important information and forward looking statements GENFIT IS A PUBLIC COMPANY LISTED ON EURONEXT PARIS (COMPARTMENT B) STOCK EXCHANGE SINCE APRIL
More informationENCORE-PH Top-line Results
ENCORE-PH Top-line Results Striving to improve human health December 5, 2018 NASDAQ CNAT Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements
More informationThe place of bariatric surgery in NASH: can we extend the indications? - No
The place of bariatric surgery in NASH: can we extend the indications? - No Nicolas Goossens Service de Gastroentérologie & Hépatologie Hôpitaux Universitaires de Genève Genève, Suisse How to extend the
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationNON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN
NON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN M. Beaugrand Service d Hépatologied Hopital J. Verdier BONDY 93143 et Université Paris XIII MAINZ 21.09.2008 ASSESSMENT OF FIBROSIS : WHY? Management
More information